Skip to content

健康溪流

US · HSTM #3266 按市值排名
33.13 -0.62 -1.84%
实时 - 追踪5344个代码 - 心跳于471秒前 · 2026-10-16 19:30

✦ 量化合理价值 计算方式说明

接近合理价值
22.41 合理价值 ≈ 38.21 54.01
  • 基于该股自身过去5年平均市盈率乘以滚动每股收益,推算出的合理价值区间为22.41-54.01。
  • 当前价格比按平均倍数计算的合理价值(38.21)低13.3%。

估值 各估值倍数与自身5年区间的对比

市净率 2.75 高于历史水平 第95百分位
5年平均 2.26 · 在Health Information Services中排名第23/41
市盈率 44.58 低于历史水平 第28百分位
5年平均 62.64 · 前瞻 44.39 · 在Health Information Services中排名第9/17
市销率 3.06 高于历史水平 第80百分位
5年平均 2.78 · 前瞻 2.92 · 在Health Information Services中排名第24/42

同业对比 Health Information Services

公司 市值 市盈率(TTM) 市净率 股息率
健康溪流 (HSTM) 1.01B 46.01 2.84 0.40%
Veeva Systems (VEEV) 50.25B 50.88 6.76 0.00%
BrightSpring Health Services (BTSG) 12.04B 36.89 5.88 0.00%
Tempus AI (TEM) 11.68B -44.94 26.24 0.00%
Hinge Health (HNGE) 8.00B 74.11 23.24 0.00%
HealthEquity (HQY) 7.61B 33.22 3.83 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★★☆ 合理价值34.00 经济护城河None 不确定性Medium

当前股价低于晨星合理价值估算2.6%。

合理价值

HealthStream Inc is assigned a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 6% discount to our quantitative fair value estimate of $34.00 per share; however, some caution is warranted due to this estimate's medium uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's solid growth bolsters our quantitative valuation. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. Reflecting the firm's growth is its EPS 5-year growth of 21.6%, which ranks in the top 20% globally. The robust five-year track record of EPS growth is reason to be optimistic about the firm's shares. We believe this is a sign that shares could be cheap.

On a different note, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 0.9, for example, lies in the bottom 40% compared with peers globally. The market value of equity makes up a large fraction of enterprise value, indicating that shares have sharply risen, or that the company has a "lazy" balance sheet that is underleveraged. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

经济护城河

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

健康溪流 讨论区 0 条评论

发表评论